Diagnostic Yield of Isolated Deamidated Gliadin Peptide Antibody Elevation for Celiac Disease

Nicholas A. Hoerter, Sarah E. Shannahan, Jorge Suarez, Suzanne K. Lewis, Peter H.R. Green, Daniel A. Leffler, Benjamin Lebwohl

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Serologic testing for celiac disease includes tissue transglutaminase and endomysial antibodies. In addition to these tools, assays for deamidated gliadin peptide antibodies have been shown to have sensitivity and specificity that are comparable to tissue transglutaminase testing, and are increasingly being used for celiac disease testing. Aims: The goal of this study is to evaluate the utility of deamidated gliadin peptide (DGP) testing in the setting of a negative tissue transglutaminase (TTG) IgA test. Methods: We reviewed the records of all patients seen at two U.S. celiac disease referral centers and identified those who had an elevated DGP IgA and/or IgG in the setting of a negative TTG IgA. Of these patients, those who underwent duodenal biopsy while on a gluten-containing diet were included. Patients with prior biopsy-proven celiac disease or prior TTG IgA positivity were excluded. The results of the biopsy were used as the gold standard for celiac disease diagnosis, and patients with villous atrophy (Marsh class 3) on duodenal biopsy were considered to have celiac disease. Results: Between the two institutions, 84 patients were identified with negative TTG IgA and positive DGP IgA or IgG who also had duodenal biopsies performed while maintaining a gluten-containing diet. Of these patients, 13 patients (15.5%; 95% CI 8.5–25.0%) were found to have celiac disease on duodenal biopsy. Conclusions: DGP antibody testing can identify cases of celiac disease in TTG-negative individuals, although the low positive predictive value suggests that the yield may be low.

Original languageEnglish (US)
Pages (from-to)1272-1276
Number of pages5
JournalDigestive Diseases and Sciences
Volume62
Issue number5
DOIs
StatePublished - May 1 2017
Externally publishedYes

Fingerprint

Gliadin
Celiac Disease
Immunoglobulin A
Peptides
Antibodies
Biopsy
Glutens
Immunoglobulin G
Diet
Wetlands
transglutaminase 2
Atrophy
Referral and Consultation
Sensitivity and Specificity

Keywords

  • Celiac disease
  • Gliadin
  • Serologic tests
  • Tissue transglutaminase

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Cite this

Hoerter, N. A., Shannahan, S. E., Suarez, J., Lewis, S. K., Green, P. H. R., Leffler, D. A., & Lebwohl, B. (2017). Diagnostic Yield of Isolated Deamidated Gliadin Peptide Antibody Elevation for Celiac Disease. Digestive Diseases and Sciences, 62(5), 1272-1276. https://doi.org/10.1007/s10620-017-4474-5

Diagnostic Yield of Isolated Deamidated Gliadin Peptide Antibody Elevation for Celiac Disease. / Hoerter, Nicholas A.; Shannahan, Sarah E.; Suarez, Jorge; Lewis, Suzanne K.; Green, Peter H.R.; Leffler, Daniel A.; Lebwohl, Benjamin.

In: Digestive Diseases and Sciences, Vol. 62, No. 5, 01.05.2017, p. 1272-1276.

Research output: Contribution to journalArticle

Hoerter, NA, Shannahan, SE, Suarez, J, Lewis, SK, Green, PHR, Leffler, DA & Lebwohl, B 2017, 'Diagnostic Yield of Isolated Deamidated Gliadin Peptide Antibody Elevation for Celiac Disease', Digestive Diseases and Sciences, vol. 62, no. 5, pp. 1272-1276. https://doi.org/10.1007/s10620-017-4474-5
Hoerter, Nicholas A. ; Shannahan, Sarah E. ; Suarez, Jorge ; Lewis, Suzanne K. ; Green, Peter H.R. ; Leffler, Daniel A. ; Lebwohl, Benjamin. / Diagnostic Yield of Isolated Deamidated Gliadin Peptide Antibody Elevation for Celiac Disease. In: Digestive Diseases and Sciences. 2017 ; Vol. 62, No. 5. pp. 1272-1276.
@article{1f915111e49e4e87bd5faf917ee962c1,
title = "Diagnostic Yield of Isolated Deamidated Gliadin Peptide Antibody Elevation for Celiac Disease",
abstract = "Background: Serologic testing for celiac disease includes tissue transglutaminase and endomysial antibodies. In addition to these tools, assays for deamidated gliadin peptide antibodies have been shown to have sensitivity and specificity that are comparable to tissue transglutaminase testing, and are increasingly being used for celiac disease testing. Aims: The goal of this study is to evaluate the utility of deamidated gliadin peptide (DGP) testing in the setting of a negative tissue transglutaminase (TTG) IgA test. Methods: We reviewed the records of all patients seen at two U.S. celiac disease referral centers and identified those who had an elevated DGP IgA and/or IgG in the setting of a negative TTG IgA. Of these patients, those who underwent duodenal biopsy while on a gluten-containing diet were included. Patients with prior biopsy-proven celiac disease or prior TTG IgA positivity were excluded. The results of the biopsy were used as the gold standard for celiac disease diagnosis, and patients with villous atrophy (Marsh class 3) on duodenal biopsy were considered to have celiac disease. Results: Between the two institutions, 84 patients were identified with negative TTG IgA and positive DGP IgA or IgG who also had duodenal biopsies performed while maintaining a gluten-containing diet. Of these patients, 13 patients (15.5{\%}; 95{\%} CI 8.5–25.0{\%}) were found to have celiac disease on duodenal biopsy. Conclusions: DGP antibody testing can identify cases of celiac disease in TTG-negative individuals, although the low positive predictive value suggests that the yield may be low.",
keywords = "Celiac disease, Gliadin, Serologic tests, Tissue transglutaminase",
author = "Hoerter, {Nicholas A.} and Shannahan, {Sarah E.} and Jorge Suarez and Lewis, {Suzanne K.} and Green, {Peter H.R.} and Leffler, {Daniel A.} and Benjamin Lebwohl",
year = "2017",
month = "5",
day = "1",
doi = "10.1007/s10620-017-4474-5",
language = "English (US)",
volume = "62",
pages = "1272--1276",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Diagnostic Yield of Isolated Deamidated Gliadin Peptide Antibody Elevation for Celiac Disease

AU - Hoerter, Nicholas A.

AU - Shannahan, Sarah E.

AU - Suarez, Jorge

AU - Lewis, Suzanne K.

AU - Green, Peter H.R.

AU - Leffler, Daniel A.

AU - Lebwohl, Benjamin

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background: Serologic testing for celiac disease includes tissue transglutaminase and endomysial antibodies. In addition to these tools, assays for deamidated gliadin peptide antibodies have been shown to have sensitivity and specificity that are comparable to tissue transglutaminase testing, and are increasingly being used for celiac disease testing. Aims: The goal of this study is to evaluate the utility of deamidated gliadin peptide (DGP) testing in the setting of a negative tissue transglutaminase (TTG) IgA test. Methods: We reviewed the records of all patients seen at two U.S. celiac disease referral centers and identified those who had an elevated DGP IgA and/or IgG in the setting of a negative TTG IgA. Of these patients, those who underwent duodenal biopsy while on a gluten-containing diet were included. Patients with prior biopsy-proven celiac disease or prior TTG IgA positivity were excluded. The results of the biopsy were used as the gold standard for celiac disease diagnosis, and patients with villous atrophy (Marsh class 3) on duodenal biopsy were considered to have celiac disease. Results: Between the two institutions, 84 patients were identified with negative TTG IgA and positive DGP IgA or IgG who also had duodenal biopsies performed while maintaining a gluten-containing diet. Of these patients, 13 patients (15.5%; 95% CI 8.5–25.0%) were found to have celiac disease on duodenal biopsy. Conclusions: DGP antibody testing can identify cases of celiac disease in TTG-negative individuals, although the low positive predictive value suggests that the yield may be low.

AB - Background: Serologic testing for celiac disease includes tissue transglutaminase and endomysial antibodies. In addition to these tools, assays for deamidated gliadin peptide antibodies have been shown to have sensitivity and specificity that are comparable to tissue transglutaminase testing, and are increasingly being used for celiac disease testing. Aims: The goal of this study is to evaluate the utility of deamidated gliadin peptide (DGP) testing in the setting of a negative tissue transglutaminase (TTG) IgA test. Methods: We reviewed the records of all patients seen at two U.S. celiac disease referral centers and identified those who had an elevated DGP IgA and/or IgG in the setting of a negative TTG IgA. Of these patients, those who underwent duodenal biopsy while on a gluten-containing diet were included. Patients with prior biopsy-proven celiac disease or prior TTG IgA positivity were excluded. The results of the biopsy were used as the gold standard for celiac disease diagnosis, and patients with villous atrophy (Marsh class 3) on duodenal biopsy were considered to have celiac disease. Results: Between the two institutions, 84 patients were identified with negative TTG IgA and positive DGP IgA or IgG who also had duodenal biopsies performed while maintaining a gluten-containing diet. Of these patients, 13 patients (15.5%; 95% CI 8.5–25.0%) were found to have celiac disease on duodenal biopsy. Conclusions: DGP antibody testing can identify cases of celiac disease in TTG-negative individuals, although the low positive predictive value suggests that the yield may be low.

KW - Celiac disease

KW - Gliadin

KW - Serologic tests

KW - Tissue transglutaminase

UR - http://www.scopus.com/inward/record.url?scp=85011556494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011556494&partnerID=8YFLogxK

U2 - 10.1007/s10620-017-4474-5

DO - 10.1007/s10620-017-4474-5

M3 - Article

C2 - 28161854

AN - SCOPUS:85011556494

VL - 62

SP - 1272

EP - 1276

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 5

ER -